Outcomes of an Intravenous to Subcutaneous Infliximab (CT-P13) Strategy in Takayasu Arteritis: A Proof-of-Concept Prospective Study

Luca Iorio; Federica Davanzo; Eleonora Fiorin; Marta Codirenzi; Roberta Prevedello; Andrea Doria; Roberto Padoan

doi:10.1002/acr2.70158

Outcomes of an Intravenous to Subcutaneous Infliximab (CT-P13) Strategy in Takayasu Arteritis: A Proof-of-Concept Prospective Study

ACR Open Rheumatol. 2026 Jan;8(1):e70158. doi: 10.1002/acr2.70158.

Authors

Luca Iorio¹, Federica Davanzo¹, Eleonora Fiorin¹, Marta Codirenzi¹, Roberta Prevedello¹, Andrea Doria¹, Roberto Padoan¹

Affiliation

¹ Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy.

Abstract

Objectives: To evaluate persistence, outcomes, safety, and remission maintenance after switching from intravenous infliximab (IV-IFX) to subcutaneous infliximab (SC-IFX, CT-P13) in patients with Takayasu arteritis (TA).

Methods: We conducted a prospective, single-center, proof-of-concept observational study of consecutive adults with TA in sustained clinical, laboratory, and positron emission tomography (PET) remission switched from stable 5 mg/kg dose IV-IFX to SC-IFX 120 mg every two weeks. Assessments at baseline, 6 months, and 12 months included Indian Takayasu Clinical Activity Score (ITAS2010), Disease Extent Index-Takayasu (Dei.TAK), PET Vascular Activity Score (PETVAS), C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), Large Vessel Vasculitis Index of Damage (LVVID), and safety data. The primary objective was 12-month drug persistence. Secondary outcomes included remission rates, changes in ITAS2010, Dei.TAK, PETVAS, acute-phase reactants, damage accrual, and safety.

Results: Nine women (median age 35 [interquartile range (IQR) 28-44] years) were included. The median IV-IFX exposure before the switch was 60 (IQR 24-72) months. Twelve-month drug persistence was 77.8%. One patient discontinued early due to an injection-site reaction, and another experienced a relapse at 12 months that required a therapy change. At 12 months, 87.5% (seven of eight) patients remained in remission. CRP and ESR remained stable (P = 0.297 and P = 0.068, respectively). PETVAS was similar to pre-switch values (P = 0.589). Median LVVID remained stable throughout follow-up. No serious adverse events occurred.

Conclusions: IV-IFX to SC-IFX switching was feasible and well tolerated and generally maintained remission over 12 months in most patients with TA, with stable metabolic imaging and no increase in damage accrual. These findings support SC-IFX as a practical maintenance strategy, warranting confirmation in larger multicenter cohorts.